InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: turks post# 12826

Wednesday, 01/31/2018 3:03:39 PM

Wednesday, January 31, 2018 3:03:39 PM

Post# of 16885
Things are definitely weird, but weird is normal for Titan.

1. All indications seem to be that Braeburn has in fact gotten rid of their sales force, in which case nothing is being sold. So, the rights should be transferred back to Titan. I was struck by the following in the press release:

"There can be no assurance that this process will result in the completion of any transaction, including, but not limited to, a new licensing agreement for Probuphine with a different partner. Titan has not set a timetable for completion of the process, and it does not intend to comment further unless a specific transaction or agreement is approved by its Board of Directors."


They didn't say there can be no assurance the rights will be returned to Titan...instead, they are already talking about a transaction or agreement that will happen once the rights do return. So, it would seem things are already happening behind the scenes.

2. Everyone is waiting to see what funding comes from the federal government. Trump said absolutely nothing about opioid funding in the SOTU. Weird, because he backed $45 billion over ten years in the attempt to get rid of Obamacare. Personally, I don't think he really cares about the issue, but he will use it as a carrot to get Democrats to agree to his budget. Currently, under America Cures there is $500 million a year allocated for 2017 and 2018. The only proposal out there right now is from the Democrats: $25 billion over the next two years ($12.5 billion in each of 2018 and 2019), a lot of which would go to medicare/medicaid to fund MAT. Sad they are playing politics with peoples lives.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News